Symptoms: Single oral doses of Erlotinib up to 1000 mg erlotinib in healthy subjects, and up to 1600 mg in cancer patients have been tolerated. Repeated twice daily doses of 200 mg in healthy subjects were poorly tolerated after only a few days of dosing. Based on the data from these studies, severe adverse reactions such as diarrhea, rash and possibly increased activity of liver aminotransferases may occur above the recommended dose.
Management: In case of suspected overdose, Erlotinib should be withheld and symptomatic treatment initiated.
Other Services
Country
Account